Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (clinicaltrials.gov) - Apr 9, 2025 - P1 | N=60 | Recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Apr 2025 ➔ Oct 2025
Enrollment open • Trial primary completion date • Oncology • Solid Tumor • HRAS • KRAS • NRAS • PD-L1
|